Immune Checkpoint Inhibitor in Early-Stage TNBC

Download these slides for an expert-curated review of the latest developments in using immune checkpoint inhibitor–based therapy to treat early-stage TNBC, followed by insights into monitoring and management of immune-related adverse events.
Heather McArthur, MD, MPH
Rita Nanda, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.23 MB
Released: December 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Related Content

Brief expert slideset from Clinical Care Options (CCO) on how and when to test for NTRK fusions in patients with head and neck cancer

Aarti Bhatia, MD, MPH Released: January 5, 2021

Brief expert slideset from Clinical Care Options (CCO) reviews current clinical trials of immunotherapies for patients with head and neck cancer

Barbara Burtness, MD Released: January 5, 2021

In this slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

Domenica Lorusso, MD, PhD person default Mansoor Raza Mirza, MD Ana Oaknin, MD, PhD Released: January 5, 2021

Video from Clinical Care Options (CCO) with global perspectives on using immunotherapy in the optimal care of patients with endometrial cancer

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue